Figures & data
Table 1. CNS recurrence patients’ characteristics at the time of diagnosis compared with patients without CNS recurrence
Figure 1. Tailored CNS-directed treatment strategies and the treatment outcome. CNS, central nervous system; CNSL, central nervous system leukemia; IT-MTX, intrathecal-methotrexate; Ara-C, cytarabine; CSI, cerebrospinal irradiation; HDMP, high-dose methylprednisolone; CNS-CR, CNS complete remission; DFS, disease-free survival; OS, overall survival. All patients underwent routine diagnostic lumbar puncture for CSF sampling and concomitantly received intrathecal (IT) cytarabine (50 mg) plus dexamethasone (5 mg) once CNS recurrence was suspected. CNS refractory disease is defined as failure to achieve a CNS-CR at the end of CNS directed treatment. CNS second recurrence is defined as the reappearance of blasts in CSF or development of clinical signs of CNS leukemia (e.g. facial nerve palsy, brain/eye involvement) after achievement of a CNS-CR.
